HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.

Abstract
Malignant pleural mesothelioma is a fatal malignancy linked to asbestos exposure. The main challenge for mesothelioma treatment is to go beyond the drug resistance, in particular against cisplatin (CDDP), one of the most used chemotherapeutic drug. 3-O-methylfunicone (OMF) is a metabolite produced by the fungus Penicillium pinophilum; its antiproliferative properties have been previously studied in vitro. Particularly, OMF is able to inhibit mesothelioma cell motility. To improve the effects of CDDP by-passing the resistance of mesothelioma cells to this drug, in the present study we investigated the combined treatment of OMF with CDDP respectively in an established mesothelioma cell line (NCI) and primary mesothelioma cells (Mest). As compared to the effect of single treatments, the combination of OMF and CDDP resulted in a stronger inhibition of NCI and Mest cell proliferation. OMF combination with CDDP was also able to affect the migratory ability of NCI and Mest cells by down-regulating αv and β5 expression and reducing metalloproteinase 2 (MMP-2) production. In addition, this association was effective in modulating VEGF gene expression. This finding highlights the possibility to use OMF and CDDP together to regulate angiogenesis and tumour progression in mesothelioma.
AuthorsElisabetta Buommino, Anna De Filippis, Rosario Nicoletti, Massimo Menegozzo, Simona Menegozzo, Maria Letizia Ciavatta, Antonietta Rizzo, Virginia Brancato, Maria Antonietta Tufano, Giovanna Donnarumma
JournalInvestigational new drugs (Invest New Drugs) Vol. 30 Issue 4 Pg. 1343-51 (Aug 2012) ISSN: 1573-0646 [Electronic] United States
PMID21656164 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3-O-methylfunicone
  • Pyrones
  • RNA, Messenger
  • Receptors, Vitronectin
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • integrin alphaVbeta5
  • Matrix Metalloproteinase 2
  • Cisplatin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Shape (drug effects)
  • Chemotaxis (drug effects, genetics)
  • Cisplatin (pharmacology, therapeutic use)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Matrix Metalloproteinase 2 (genetics, metabolism)
  • Mesothelioma (drug therapy, genetics, pathology)
  • Penicillium (chemistry)
  • Pyrones (pharmacology, therapeutic use)
  • RNA, Messenger (genetics, metabolism)
  • Receptors, Vitronectin (genetics, metabolism)
  • Vascular Endothelial Growth Factor A (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: